secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001558370-23-006964
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma gets FDA approval for Adzenys site transfer; 15% margin improvement expected
--------------------------------------------------------------------------------

- FDA approved Prior Approval Supplement to transfer Adzenys XR-ODT manufacturing to contract manufacturer in 2023.
- Cotempla XR-ODT bioequivalence study completed; site transfer PAS submission expected mid-2023 with approval by late 2023 or early 2024.
- Upon completion of both site transfers, Aytu expects 15% margin improvement for ADHD product line.
- Manufacturing of Adzenys and Cotempla at contract facility expected to begin late 2023 and early 2024 respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023006964/0001558370-23-006964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023006964/aytu-20230427x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-006964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer